Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies

被引：0

作者：

Liu, Shufang ^{[1
,2
]}

Niu, Wenquan ^{[3
]}

机构：

[1] Beijing Univ Chinese Med, Grad Sch, Beijing, Peoples R China

[2] China Japan Friendship Hosp, Dept Pediat, Beijing, Peoples R China

[3] China Japan Friendship Hosp, Inst Clin Med Sci, 2 Yinghua East St, Beijing 100029, Peoples R China

来源：

JAMA ONCOLOGY | 2020年 / 6卷 / 02期

关键词：

METAANALYSIS;

D O I：

10.1001/jamaoncol.2019.5148

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：298 / 299

页数：2

共 50 条

[1] Different Biomarker Modalities and Response to Anti-PD-1/PD-L1 Therapies Reply
Lu, Steve
Wang, Hao
Taube, Janis M.
[J]. JAMA ONCOLOGY, 2020, 6 (02) : 299 - 299
[2] The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
Sui, Xinbing
Ma, Junhong
Han, Weidong
Wang, Xian
Fang, Yong
Li, Da
Pan, Hongming
Zhang, Li
[J]. ONCOTARGET, 2015, 6 (23) : 19393 - 19404
[3] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino
Gerardo Botti
Paul Lorigan
Giuseppe V. Masucci
Jason D. Hipp
Christine E. Horak
Ignacio Melero
Paolo A. Ascierto
[J]. Drugs, 2016, 76 : 925 - 945
[4] Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Festino, Lucia
Botti, Gerardo
Lorigan, Paul
Masucci, Giuseppe V.
Hipp, Jason D.
Horak, Christine E.
Melero, Ignacio
Ascierto, Paolo A.
[J]. DRUGS, 2016, 76 (09) : 925 - 945
[5] Is anti-PD-1/PD-L1 immunotherapy sensitizing for conventional cancer therapies?
Matias, M.
Aspeslagh, S.
Palomar, V.
Lanoy, E.
Dercle, L.
Even, C.
Ferte, C.
Hollebecque, A.
Marabelle, A.
Massard, C.
Soria, J-C.
Postel-Vinay, S.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[6] Pneumonitis with anti-PD-1/PD-L1 therapy
Naidoo, J.
Cunningham, J.
Woo, K. M.
Hellmann, M. D.
Postow, M. A.
Drilon, A. E.
Chaft, J. E.
Lesokhin, A. M.
Segal, N. H.
Callahan, M. K.
Rudin, C. M.
Iyriboz, T.
Wolchok, J. D.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S103 - S103
[7] Impact of PD-L1 feedback modulation on the sensitivity of anti-PD-1/PD-L1
Zhu, Jian
Zhu, Rebecca L.
[J]. CANCER RESEARCH, 2019, 79 (13)
[8] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen
Alexander C. Huang
Wei Zhang
Gao Zhang
Min Wu
Wei Xu
Zili Yu
Jiegang Yang
Beike Wang
Honghong Sun
Houfu Xia
Qiwen Man
Wenqun Zhong
Leonardo F. Antelo
Bin Wu
Xuepeng Xiong
Xiaoming Liu
Lei Guan
Ting Li
Shujing Liu
Ruifeng Yang
Youtao Lu
Liyun Dong
Suzanne McGettigan
Rajasekharan Somasundaram
Ravi Radhakrishnan
Gordon Mills
Yiling Lu
Junhyong Kim
Youhai H. Chen
Haidong Dong
Yifang Zhao
Giorgos C. Karakousis
Tara C. Mitchell
Lynn M. Schuchter
Meenhard Herlyn
E. John Wherry
Xiaowei Xu
Wei Guo
[J]. Nature, 2018, 560 : 382 - 386
[9] Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Chen, Gang
Huang, Alexander C.
Zhang, Wei
Zhang, Gao
Wu, Min
Xu, Wei
Yu, Zili
Yang, Jiegang
Wang, Beike
Sun, Honghong
Xia, Houfu
Man, Qiwen
Zhong, Wenqun
Antelo, Leonardo F.
Wu, Bin
Xiong, Xuepeng
Liu, Xiaoming
Guan, Lei
Li, Ting
Liu, Shujing
Yang, Ruifeng
Lu, Youtao
Dong, Liyun
McGettigan, Suzanne
Somasundaram, Rajasekharan
Radhakrishnan, Ravi
Mills, Gordon
Lu, Yiling
Kim, Junhyong
Chen, Youhai H.
Dong, Haidong
Zhao, Yifang
Karakousis, Giorgos C.
Mitchell, Tara C.
Schuchter, Lynn M.
Herlyn, Meenhard
Wherry, E. John
Xu, Xiaowei
Guo, Wei
[J]. NATURE, 2018, 560 (7718) : 382 - +
[10] In Vivo Syngeneic Tumor Models with Acquired Resistance to Anti-PD-1/PD-L1 Therapies
Denis, Morgane
Grasselly, Chloe
Choffour, Pierre-Antoine
Wierinckx, Anne
Mathe, Doriane
Chettab, Kamel
Tourette, Anne
Talhi, Nolan
Bourguignon, Aurore
Birzele, Fabian
Kress, Elsa
Jordheim, Lars Petter
Klein, Christian
Matera, Eva-Laure
Dumontet, Charles
[J]. CANCER IMMUNOLOGY RESEARCH, 2022, 10 (08) : 1013 - 1027

← 1 2 3 4 5 →